Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma is a research paper published in Pharmaceutics (2022). On theSindex it has a DataRank of 0.511. It has been cited 7 times, with 7 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.312
From this paper's citation signal
Citation Network Contribution
0.199
From 5 citing papers with measurable signal
Ministry of Science and Technology
Grant: 108-2314-B-006-086-MY2
Ministry of Science and Technology
Grant: NCKUH-11105007
Ministry of Science and Technology
Grant: NCKUH-11103058
Ministry of Science and Technology
Grant: NCKUH-11104019
Hung-Tsung Wu
Grant: 110-2314-B-906-002- and 110-2314-B-006-116-MY3
Higher Education Sprout Project
FWCI
0.75
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals